OraSure Q2 revenue rises on higher diagnostics sales - OSUR News | Rallies
OraSure Q2 revenue rises on higher diagnostics sales O OSUR • 2026-08-05 Outlook
OraSure Technologies guides Q3 2026 revenue at $29.5 mln to $32.5 mln
Quarterly results
US diagnostic test maker's Q2 revenue fell 2% yr/yr, core business revenue flat
Diagnostics revenue grew 1% yr/yr, driven by higher syphilis and Sickle SCAN sales
Company repurchased $2 mln in stock during Q2, totaling $22 mln under authorization
Result drivers and key details
Diagnostics sales - Co said diagnostics revenue grew 1% yr/yr due to higher syphilis test sales and addition of Sickle SCAN salesGross margin improvement - Co reported improved gross margin in Q2, up to 43.5% from 42.1% yr/yrInnovation milestones - Co highlighted FDA clearance for Colli-Pee Dx urine collection device and EUA for OraQuick Ebola 2.0 Rapid Antigen Test
Metric Beat/Miss Actual Consensus Estimate Q2 Revenue Beat $30.60 mln $29.06 mln (1 Analyst) Q2 Gross Margin 43.50% Q2 Adjusted Operating Income Beat -$14.70 mln -$19.76 mln (1 Analyst) Q2 Operating Income
The one available analyst rating on the shares is "hold". The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy." Wall Street's median 12-month price target for OraSure Technologies Inc is $4.00, about 4.1% below its August 4 closing price of $4.17.
2026-08-05
OSUR•
